Print ISSN: 0027-1446

Online ISSN: 2309-6217

Main Subjects : neurology


Assessment of neuropathological findings and medical treatment of Parkinson disease: A review of literature

Rand Abdulateef Abdullah

Annals of the College of Medicine, Mosul, 2022, Volume 44, Issue 1, Pages 10-13
DOI: 10.33899/mmed.2022.133096.1138

ABSTRACT
Background: Parkinson disease is a long-lasting and progressive motor disorder which is identified by three critical motor symptoms which are bradykinesia, rigidity and tremor. 
Aim of the study: To assess the histopathological changes in the brain of Parkinson disease’s patients and the regimes used for treatment.
Conclusion: Several histopathological changes in the neurons in brain of patients with Parkinson disease are α-synucleinopathies, lewy bodies, damage of synaptic neurons, and hyperactivation of microglial cell. Many regimes were used in the treatment of Parkinson disease particularly to alleviate motor symptoms. The golden goal is they should focus on preserving the synaptic neurons before they get damaged. 

Role of High Mobility Group Box-1 in Status Epilepticus, From Pathophysiology to Biomarker and Therapeutic Potential

Rana M. Raoof; Muna Al-Hamdany; Khalida I. Noel

Annals of the College of Medicine, Mosul, 2022, Volume 44, Issue 1, Pages 37-41
DOI: 10.33899/mmed.2021.131944.1121

Status epilepticus (SE) is a neurological emergency that require prompt diagnostic and treatment measures due to its associated mortality and morbidity. The role of neuro-inflammation in status epilepticus has been studied extensively and many potential molecules have been proposed as a promising biomarkers and therapeutic targets for the condition. Inside the nucleus, HMGB1 is a DNA-binding protein with many housekeeping functions. Under certain conditions, HMGB1 will be translocated to the extracellular space promoting a strong pro-inflammatory reaction with activation of many downstream inflammatory pathways related to seizure onset and progression. In this review the potential role of HMGB1 in the pathogenesis of SE was highlighted stressing on the promising implications of this molecule as a therapeutic target for SE.